Regis DuvalChief Executive Officer
Regis has been Senior Vice President Commercial Operations EMEA at BioRad Laboratories with responsibility for a staff of ca.1.200.
Before BioRad, Regis held a number of senior sales and marketing positions at GE Healthcare Life Science and Whatman PLC. He is a French national and holds an MBA in Strategy and Finance from the University of Westminster, London.
Dr Burkhard WittekChairman
Dr Wittek holds an MBA from Harvard Business School. After working for Dresdner Bank AG he spent 13 years with The Boston Consulting Group where he was a senior partner with worldwide responsibility for the consumer goods retail and healthcare sectors.
In 1990 he founded FORUM Family Office GmbH, which makes long-term investments in German Private Equity and European Small and Midcap publicly quoted companies. The healthcare sector is a focus area of FORUM as well as companies undergoing transitions.
Mr Till Bengt CampeNon-executive Director
Mr. Till Campe is an investment manager of FORUM Family Office GmbH. Mr. Campe joined FORUM in 2011. He holds a BA in Ancient and Modern History from the University of Oxford.
Mr Roland SackersNon-executive Director
Roland is Chief Financial Officer and Managing Director of QIAGEN N.V. and joined IDS in 2011 as Non-executive Director and Chair of the Audit Committee. As CFO, Roland spearheads the creation and execution of long-term financial plans which enable QIAGEN to execute its accelerated growth strategy.
He was responsible for numerous financing activities both on the equity side and the debt capital side with a total value of more than US$3bn, which supported more than 25 M&A transactions and led to significant revenue and profit growth. Roland holds a Masters Degree in Business Administration (Diploma Kaufmann) from the University of Münster.
He joined QIAGEN in 1999 and has been CFO since 2004. He topped ratings of Biotech CFO’s in a survey released by Thomson Reuters in 2011. Prior to joining QIAGEN, he acted as an auditor with Arthur Andersen. Roland is a Board member of the industry association BIO Deutschland as well as member of the board of directors and head of the audit committee of QIAGEN Marseille (formerly Ipsogen S.A.).
Mr Peter WilliamsonNon-executive Director
Peter joined IDS as Non-executive Director on 15th June 2015. Peter holds a Master of Business Administration from the University of Edinburgh. Between 1993 and 2010 worked in various positions for BTR Automotive, Metzeler, Trelleborg, Xerium Technologies and IBP Group in locations in Europe, USA and Asia. Since 1999 he has worked in businesses owned by private equity with Metzeler belonging to CVC and Xerium Technologies an Apax portfolio business. His final executive position was as Group CEO for IBP Group (a Sun Capital Partner portfolio business) and since then has worked as an operating partner for Better Capital and currently has a portfolio of Non-executive appointments.
Dr. Peter KasparNon-executive Director
Peter Kaspar has over 35 years experience in life sciences and diagnostics. From 2005 to 2011, he was a member of the Management Committee of bioMérieux S.A where he worked as Head of the Molecular Diagnostics unit, Head of Global Research & Development and Head of the Microbiology unit. Prior to bioMérieux, he spent a significant part of his career with Roche Diagnostics (formerly Boehringer Mannheim GmbH) in Europe, Latin America and the US, with responsibilities in strategy, business development and R&D management. He holds a PhD in biochemistry from the University of Muenster.
Mr Paul MartinFinance Director
Paul joined IDS as Finance Director on 4 January 2016. Previously Paul was based in Singapore as CFO of Volex plc’s Power Division, a major manufacturer of electrical power cables with operations throughout Asia.
Paul qualified as a Chartered Accountant with Deloitte in 2002, and subsequently worked in a number of senior finance roles in the technology sector